1. SARS-CoV-2 and Covid-19 Immunopathogenesis
- Author
-
Julia Neves Becil, Thaise Farias Rodrigues, Maria Polyanna Rebouças, Emanuelly Maria Lima Barbosa, João Victor Oliveira de Melo, Carlos Eduardo Colares Soares, Beatriz Mella Soares Pessoa, Maria Cristina Dos-Santos, Antonio Luiz Boechat, Pedro Henrique Aquino Gil de Freitas, Cecília Tizatto Barroso, Vanessa Ferreira, Rebeka Bustamante Rocha, Isabela de Araújo Seffair, Natascha Rodrigues, David José Conceição Vila, and Rosmery Ubiera
- Subjects
Coronavirus disease 2019 (COVID-19) ,biology ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,viruses ,virus diseases ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Virology ,immunology ,medicine ,biology.protein ,Cytokine storm ,business ,Interleukin 6 - Abstract
The coronavirus disease 2019 (COVID-19) is now a global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike other known coronaviruses, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 reveals new clinical, immunological, and pathologic features. The lymphocyte depletion, macrophage and neutrophil hyperactivation, cytokine dysregulation, thrombophilia, delayed antiviral response, and immune exhaustion are key immunological findings linked to the clinical progression of this disease. Understanding and identifying the underlying immunological basis of COVID-19 is crucial to designing effective therapies. Here, we provide an overview of immunopathogenesis driven by SARS-CoV-2 after its interactions with the immune system.
- Published
- 2020